| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BRMS1;;BRMS1 |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human BRMS1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于BRMS1抗体的3篇参考文献示例(注：文献信息为模拟，实际引用时请核实原文)：
1. **"BRMS1 suppresses breast cancer metastasis by multiple mechanisms"**
- **作者**: Seraj MJ, et al.
- **摘要**: 该研究通过Western blot和免疫组化分析，证实BRMS1蛋白在乳腺癌细胞中高表达可显著抑制转移，但不影响原发肿瘤生长。研究利用BRMS1抗体验证了其在转移抑制中的关键作用，并探讨其通过调控NF-κB通路抑制转移的机制。
2. **"Epigenetic regulation of BRMS1 in metastatic melanoma"**
- **作者**: Zhang S, et al.
- **摘要**: 本文通过免疫荧光和流式细胞术，结合BRMS1抗体检测黑色素瘤细胞中BRMS1的亚细胞定位及表达水平。研究发现，BRMS1的低表达与启动子甲基化相关，且其恢复表达可抑制黑色素瘤细胞的侵袭能力。
3. **"BRMS1 interacts with histone modifiers to regulate metastasis"**
- **作者**: Samant RS, et al.
- **摘要**: 研究使用BRMS1抗体进行免疫共沉淀(Co-IP)实验，发现BRMS1与组蛋白脱乙酰化酶(HDACs)及甲基转移酶形成复合物，通过表观遗传调控靶基因(如CXCR4)抑制肿瘤转移。该机制为BRMS1的转移抑制功能提供了新视角。
建议通过PubMed或Google Scholar以“BRMS1 antibody”和“metastasis”等关键词检索最新文献以获取准确信息。
BRMS1 (Breast Cancer Metastasis Suppressor 1) antibody is a tool used to detect the BRMS1 protein, a key player in suppressing tumor metastasis, particularly in breast cancer. Discovered in the early 2000s, BRMS1 is located on chromosome 11q13.2 and functions as a metastasis suppressor by regulating gene expression networks involved in invasion, angiogenesis, and cell survival. It interacts with histone deacetylase (HDAC) complexes to modify chromatin structure, thereby repressing pro-metastatic genes like osteopontin and EGFR. BRMS1 also modulates signaling pathways such as NF-κB and PI3K/Akt, limiting metastatic potential without affecting primary tumor growth.
BRMS1 antibodies are widely used in research to study its expression patterns, subcellular localization (predominantly nuclear), and correlation with clinical outcomes. Reduced BRMS1 levels are associated with increased metastasis and poor prognosis in breast cancer and other malignancies like melanoma and ovarian cancer. These antibodies enable techniques including Western blotting, immunohistochemistry (IHC), and immunofluorescence to explore BRMS1's role in metastasis suppression, therapeutic resistance, and its potential as a biomarker. Recent studies also investigate BRMS1's involvement in exosome-mediated communication and metabolic reprogramming, expanding its relevance in cancer biology.
×
